These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32505524)

  • 41. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation.
    Taylor-Cousar JL; Jain R
    J Cyst Fibros; 2021 May; 20(3):402-406. PubMed ID: 33762125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 43. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
    Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C;
    Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738
    [No Abstract]   [Full Text] [Related]  

  • 44. At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash.
    Muirhead C; Verzasconi D; Joshi S
    Pediatr Pulmonol; 2022 Jul; 57(7):1779-1781. PubMed ID: 35451238
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
    Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
    J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
    Burki TK
    Lancet Respir Med; 2019 Sep; 7(9):739-740. PubMed ID: 31353281
    [No Abstract]   [Full Text] [Related]  

  • 48. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

  • 49. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 50. No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.
    Vonk SEM; Terheggen-Lagro SWJ; Mouissie LM; Mathôt RAA; Kemper EM;
    J Cyst Fibros; 2022 Jan; 21(1):e5-e7. PubMed ID: 34756823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
    Jennings MT; Flume PA
    Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genomically-guided therapies: A new era for cystic fibrosis.
    Fajac I; Girodon E
    Arch Pediatr; 2020 Feb; 27 Suppl 1():eS41-eS44. PubMed ID: 32172937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International disparities in diagnosis and treatment access for cystic fibrosis.
    Guo J; King I; Hill A
    Pediatr Pulmonol; 2024 Jun; 59(6):1622-1630. PubMed ID: 38558542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 56. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.
    Habib AR; Kajbafzadeh M; Desai S; Yang CL; Skolnik K; Quon BS
    Sci Rep; 2019 May; 9(1):7234. PubMed ID: 31076617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
    [No Abstract]   [Full Text] [Related]  

  • 58. Entering the era of highly effective modulator therapies.
    Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
    Kim J; Davies Z; Dunn C; Wine JJ; Milla C
    J Cyst Fibros; 2018 Mar; 17(2):179-185. PubMed ID: 29279204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An acneiform eruption associated with elexacaftor/tezacaftor/ivacaftor treatment.
    Breneman A; Soliman YS; Gallitano SM
    Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.